相关实验视频

Updated: May 30, 2025

Assessment of the Metabolic Profile of Primary Leukemia Cells

Published on: November 21, 2018

基本血小板血症:一个审查

Ayalew Tefferi¹, Naseema Gangat¹, Giuseppe Gaetano Loscocco²

¹Division of Hematology, Department of Medicine, Mayo Clinic, Rochester, Minnesota.

|January 27, 2025

概括

骨髓扩散性瘤,增加了血栓形成和出血的风险. 根据个体风险因素,治疗包括低剂量阿司匹林或细胞减肥药物.

科学领域:

血液学
癌症学

背景情况:

基本血小板血 (ET) 是一种克隆性骨髓增殖性瘤,其特征是血小板的过度产生.
ET与血栓形成和出血并发症的风险增加有关.
美国每年ET发病率大约为每10万人中1. 5人.

研究的目的:

总结临床特征,风险因素和基本血小板病的治疗策略.
突出ET患者血栓和出血的风险增加.
根据个体患者的风险概况讨论治疗方法.

主要方法:

关于精髓血栓瘤的现有文献的综述.
对患者发病率,遗传突变和临床结果的分析.
对预防血栓形成的治疗疗效的评估.

主要成果:

血小板数 ≥450 × 10^9/ L 的患者有动脉血栓 (11%) 和静脉血栓 (7%),以及出血 (8%) 的风险增加.
主要的遗传驱动因素包括JAK2 (64%),CALR (23%) 和MPL (4%),影响血栓形成的风险.
血栓形成的危险因素包括先前的血栓形成,年龄超过60岁,JAK2突变和心血管因素.
大多数ET患者推服用低剂量阿司匹林;高危人群中,氨酸可显著降低血栓事件.

结论:

本质性血栓塞瘤需要分层管理风险,以减轻血栓,出血和可能发展为骨髓纤维化或急性骨髓性白血病.
治疗策略包括低剂量阿司匹林用于降低风险,以及高风险患者的细胞减肥疗法 (例如基尿素).
持续监测对于管理ET及其相关并发症至关重要.

更多相关视频

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Flow Cytometry Analysis of Tissue Factor Expression in Human Platelets

Published on: November 22, 2024

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Pre-clinical Evaluation of Tyrosine Kinase Inhibitors for Treatment of Acute Leukemia

Published on: September 18, 2013

相关概念视频

Structure and Function of Platelets

Structure and Function of Platelets

The cell fragments known as platelets are disc-shaped, with an average diameter of about 3 μm and a thickness of roughly 1 μm. They play a crucial role in the body's vascular clotting system, which also involves plasma proteins, blood cells, and blood vessel tissues.
Platelets are continually replenished, circulating in the bloodstream for 9-12 days before being removed by phagocytes, primarily in the spleen. A microliter of circulating blood contains between 150,000 and 450,000...

Disorders of Hemostasis

Disorders of Hemostasis

Hemostasis, the process that stops bleeding after a blood vessel injury, is crucial for maintaining the integrity of the circulatory system. However, disorders of hemostasis can disrupt this delicate balance, leading to either excessive clotting or bleeding. These disorders can be broadly classified into thromboembolic disorders and bleeding disorders.
Thromboembolic Disorders
Two factors primarily cause thromboembolic conditions.

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...